东诚药业上半年净利8865.25万元，同比下降20.7%

Core Insights - Dongcheng Pharmaceutical (002675) reported a revenue of 1.384 billion yuan for the first half of 2025, representing a year-on-year decrease of 2.6% [1] - The net profit attributable to shareholders was 88.6525 million yuan, down 20.7% year-on-year [1] Revenue Breakdown - The nuclear medicine segment generated sales of 503 million yuan, an increase of 0.78% year-on-year [1] - The raw material drug segment reported sales of 611 million yuan, a decline of 7.02% year-on-year [1] - The formulation segment achieved sales of 182 million yuan, reflecting a growth of 1.76% year-on-year [1]